Introduction: Randomized Controlled Trials (RCT), particularly of rare tumour groups, often have issues with patient accrual, which necessitates a multicentre approach to achieve accrual targets. Logistically, investigators of multicentre trials face issues in efficient data management in terms of accuracy, transfer, security, and quality assurance. Historically, paperbased report forms to collect patient baseline and regular follow up data have made these issues challenging. Purpose: To discuss the use of electronic forms (eForms) used for our glioblastoma multiforme (GBM) trial study. Various limitations and advantages of the use of eForms are discussed and compared to paper based and other internet based data collection methods Methods and Materials: Specially formatted computer based PDF forms were completed to gather patient by the investigators for screening and eligibility data (eForm A and B), as well as baseline QOL eForms (quality of life data according to EORTC QLQ-C30 and QLQ-BN20 questionnaires). After randomization, radiation treatment details (eForm C) and QOL data were collected. eForm D was used to collect follow up data. All of these forms were completed by the participating centre and then emailed as an attachment to the Data Management Centre (DMC). A short satisfaction survey was sent to the physicians of the participating centres after the completion of the study. Results: For this study, there were 12 participating centres from around the world. There were no issues overall with data collection using the eForms. The costs associated with the development of the eForms were minimal as well. The forms were a convenient way of sending patient trial data via email to the DMC. The results of the short survey agree with our experience. About 90% of the participating sites found the design of the forms to be user-friendly, and did not have any problems accessing, completing, and submitting the files from their computer. Most of the participants found the eForms to be very practical, efficient, and standardized. About 20% of the participants found the need for a guide to be associated with the eForms for better standardization and minimizing bias. We did not find any problems with the security of using eForms as well.
Conclusions:
In the setting of multicentre trials, using eForms for data management proved to be efficient, convenient, and reliable. Future multicentre trials may benefit from similar data management systems to improve data collection and analysis. Purpose: Stereotactic ablative radiotherapy (SABR) is a guideline-specified treatment option for early-stage lung cancer. However, significant post-treatment fibrosis can occur and confound the detection of local recurrence. The goal of this study was to assess physician ability to detect timely local recurrence on computed tomography (CT) imaging, and compare physician performance with that of a radiomics tool. Radiomics aims to extract more complex information from medical images, including features not easily visible with the naked eye. Methods and Materials: CT scans of 45 patients (15 with proven local recurrence matched to 30 with no local recurrence) were used to measure physician and radiomic performance in assessing response. Scans were individually scored by three thoracic radiation oncologists and three thoracic radiologists, all of whom CARO 2016 S47 _________________________________________________________________________________________________________ were blinded to clinical outcomes. Radiomic features (firstorder, second-order grey-level co-occurrence matrix, and sizeand shape-based) were extracted from the same images. Performance of the physician assessors and the radiomics signatures were compared. Results: A total of 182 follow up CT scans were analyzed with a median imaging follow up of 20 months. When taking into account all CT scans during the entire follow up period, median sensitivity for physician assessment of local recurrence was 83% (range 67-100%) and specificity was 75% (range 67-87%), with only moderate inter-observer agreement (kappa=0.54). The median time to detection of recurrence across all observers was 15.5 months. When predicting recurrence using images acquired < 6 months post-SABR, physicians assessed the majority of images as benign injury/no recurrence, with a mean error of 35%, false positive rate (FPR) of 1%, and false negative rate (FNR) of 99%. At the same time point, a radiomic signature consisting of five post-SABR image appearance features in the consolidative and surrounding peri-consolidative regions demonstrated excellent discrimination, with an area under the receiver operating characteristic curve of 0.85, leave-one-out cross-validation classification error of 24%, FPR of 24%, and FNR of 23%. Conclusions: These results suggest that radiomics can detect early changes associated with local recurrence that are not typically considered by physicians. Patients with recurrence tend to have increased presence of ground-glass opacity surrounding consolidative changes compared to patients with benign injury at this early follow up time point. These appearances detected by radiomics may be early indicators of the promotion and progression to local recurrence; our ongoing studies include using correlative histology to determine their composition. This has the potential to lead to a clinically useful computer aided decision support tool based on routinely acquired CT imaging, which could lead to earlier life-saving salvage opportunities for patients with local recurrence following SABR. Purpose: A fused deposition modeling three dimensional printer is currently being commissioned at our centre for fabrication of electron bolus. The main advantage in using a 3D printer for this purpose is that virtually any shape can be produced, potentially providing a more accurate way to compensate for irregular surfaces that can change the dose distribution within the patient. PLA is one of the most commonly used 3D printer materials. Compared to ABS, PLA is less likely to warp due to heating and cooling during printing. For less expensive printers which may not have heated printing beds or thermally controlled environments, it is especially appealing. Before PLA boluses can be clinically used, their physical and dosimetric properties must be characterized. The purpose of this study was to characterize the density, dimensional accuracy, uniformity, and attenuation of PLA boluses fabricated with our printer. Methods and Materials: Several uniform solid square slabs were printed with specific requested dimensions and 100% infill using concentric and rectilinear fill patterns. These pieces were imaged using an x-ray flat panel imager in order to check for uniformity of the print. The PLA slabs were placed on solid water and irradiated with a 12 MeV electron beam. Percentage depth doses (PDDs) were measured downstream of the slabs using a parallel plate chamber and compared to measurements in water. The dimensions of the PLA slabs were measured using digital calipers in several locations, and the average was compared to design values. The slabs were also weighed using a digital scale to find their average density relative to water.
ON THE PHYSICAL AND DOSIMETRIC PROPERTIES OF 3D PRINTED ELECTRON BOLUS FABRICATED USING POLYLACTIC ACID
Results: X-ray imaging showed that certain fill patterns can create local errors in density where the printer's extruder changes direction. This can produce significant changes in dosein one case there was a > 10% surface dose directly under the defect. Fill patterns which eliminate changes in extruder direction in sensitive regions (e.g. a rectilinear pattern) eliminated such defects. PLA causes the electron PDD to shift towards shallower depths, compared to water, by 1.7 mm for each centimeter of PLA due to its increased density. This can be taken into account during treatment planning, provided the thickness of PLA is roughly constant over the area to be treated. This may not be the case if treating very large regions with complex contours. Agreement with design dimensions was within 1 mm in the plane of the printer bed, and within 1/3 of a millimeter (roughly the thickness of a single layer), perpendicular to the printer bed. Average density relative to water was in the range 1.20 -1.22. Conclusions: 3D printing shows great promise for use in fabricating electron bolus. This work indicates that PLA can be a suitable material provided the increased attenuation is properly accounted for. 
Purpose:
To develop and test a radiochromic-based in-vivo skin dosimetry protocol for permanent breast 103Pd seed implant brachytherapy (PBSI) and to compare measured doses with the calculated by a commercial TG43-based treatment planning system. Methods and Materials: EBT3 radiochromic films were calibrated using an ad-hoc acrylic phantom and 103Pd seeds. EBT3 films strips from the calibrated EBT3 batch and measuring approximately 2x15 cm2 were positioned directly over the breast skin of 13 patients implanted with103Pd seeds. The EBT3 filmstrips were positioned immediately after the PBSI procedure and were centred on the skin projection of the patient's seroma and were fixed to the breast skin of the patients using TransporeTM film. No gauze or any other material was placed on top of the EBT3 filmstrip. However, a TagadermTM transparent film dressing was placed over the area of the implant to prevent direct contact of the EBT3 filmstrip with the patient's skin. The average exposure time for the films was four hours. The films were evaluated at least 24 hours after exposure following an in house EBT3 radiochromic evaluation protocol. The maximum actual measured dose defined as the 10x10 mm2 region that exhibited the maximum net optical density on the filmstrip was used to estimate the dose to the breast skin by integration over the life of the 103Pd seeds. The maximum dose to the skin at the filmstrip position was also calculated using the TG43-based MIM MAESTROTM treatment planning system (TPS). A structure extending 0.5 mm from the body was constructed to mimic the filmstrip, at position at a similar location with respect to the seroma. The dose within the filmstrip was obtained as the maximum dose to a volume of 10x10x0.5 mm3 (0.05 cm3). Results: In general the dose calculations underestimated the EBT3-based measurements. For the highest dose measured (81.3 ± 4.9 and 82.3 ± 3.0 Gy) the corresponding calculated doses were slightly lower (7% on average). For the intermediate dose range (40 to 60 Gy, seven patients) the dose calculations were approximately 50% lower than the measured doses. For the lowest doses measured (20-40 Gy, four patients), the calculated dose were on average 15% lower than the measured. The good agreement at high and low doses is unexpected given the expected dose overestimation of the TG43-based TPS. The large
